Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 vs Chemotherapy in Platinum-Resistant Ovarian Cancer
NCT06751485Phase 3Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 3, randomised, open-label trial of anbenitamab repodatecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Alphamab Oncology. Primary endpoint: Progression-free Survival at 22 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
anbenitamab repodatecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06751485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751485.